Summit Therapeutics Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Robert W. Duggan
- Full Time Employees
- 265
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 601 Brickell Key Drive Miami FL United States of America 33131
- IPO Date
- Mar 5, 2015
- CIK
- 0001599298
- Website
- smmttx.com
- Similar Companies
- Business
- Summit Therapeutics Inc. (Nasdaq: SMMT) is a biopharmaceutical company focused on the discovery, development, and commercialization of oncology therapies. The company develops ivonescimab, a novel bispecific antibody combining PD-1 blockade for immunotherapy with anti-VEGF-mediated anti-angiogenesis effects; ivonescimab is in global Phase III clinical trials, including HARMONi and HARMONi-3 for EGFR-mutated non-small cell lung cancer (NSCLC), HARMONi-6 for squamous NSCLC, HARMONi-7, and the recently announced HARMONi-GI3 for first-line metastatic colorectal cancer, with over 2,800 patients treated to date across trials. Summit holds exclusive licenses for ivonescimab in the United States, Canada, Europe, Japan, Latin America, the Middle East, and Africa, while partner Akeso, Inc. retains rights in other regions and conducts trials in China and Australia. Founded in 2003 and headquartered in Miami, Florida, with additional offices in Menlo Park, California, and Oxford, UK, the company targets solid tumors such as NSCLC and colorectal cancer. Recent developments include a $500 million private placement in October 2025 to fund operations and U.S. trial site openings for HARMONi-GI3 by year-end; collaborations with Pfizer to combine ivonescimab with antibody-drug conjugates and with Revolution Medicines for RAS(ON) inhibitors in NSCLC, pancreatic ductal adenocarcinoma, and colorectal cancer; positive HARMONi-6 top-line results in 2025 showing a 40% reduction in progression or death risk in squamous NSCLC; and completion of HARMONi enrollment with favorable survival trends in Western patients.
Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for First-Line Treatment of Patients with Squamous Non-Small Cell Lung Cancer
Summit Therapeutics (NASDAQ:SMMT) Stock Price Crosses Above 50-Day Moving Average – Time to Sell?
These New Drugs Could Fuel Fresh Highs for Biotech and Pharma Stocks
Lowey Dannenberg, P.C. is Investigating Summit Therapeutics Inc. (NASDAQ: SMMT) for Potential Breaches of Fiduciary Duty
Summit Therapeutics Further Expands Ivonescimab Global Development Program with Phase II/III HARMONi-GU1 Study in 1L Bladder Cancer
Jim Cramer Calls Summit Therapeutics A 'Great Spec,' Recommends Buying This Consumer Cyclical Stock
Summit Therapeutics PLC (NASDAQ:SMMT) Receives Average Rating of “Hold” from Analysts
Summit Therapeutics: Upgrading To Hold As Critical Approval Decision Approaches
Kuehn Law Encourages Investors of Summit Therapeutics Inc. to Contact Law Firm
Summit Therapeutics Flags Going Concern Risk Over Cash Needs
SMMT's Q2 Loss Wider Than Expected, Ivonescimab Development in Focus
Summit Therapeutics Inc. (SMMT) Q2 2026 Earnings Call Transcript
Summit Therapeutics Q2 Earnings Call Highlights
Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2026
SMMT Shares Updated Ivonescimab Survival Data From NSCLC Study
Arcus Biosciences and Summit Therapeutics Enter Into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney Cancer
Summit Therapeutics: 'Buy' On Ivonescimab's November PDUFA And Impressive Partner Data
Summit Therapeutics Says Extended Follow-Up Reveals Stronger Survival Advantages with lead Cancer Drug
These major drug stocks rally after Trump's zero tariff announcement
Ivonescimab Plus Chemotherapy Shows Consistent, Favorable Overall Survival Results in Western and Asian Patients in Updated Analysis from Global Phase III HARMONi Study